Latest News

In omalizumab-resistant chronic spontaneous urticaria (CSU), tofacitinib rapidly calmed symptoms, but relapses varied.

Victoria Werth, MD, highlights CLE treatment gaps and how BDCA2-targeting litifilimab may quickly curb interferon-driven skin disease with less toxicity.

Takeda’s recent announcement of positive top-line phase 3 results for zasocitinib (TAK-279) places this investigational agent squarely within that evolving conversation.

Bispecific and trispecific biologics are being developed to achieve deeper clearance and more meaningful symptom relief.

Modern hidradenitis suppurativa (HS) management prioritizes restoration of function and quality of life, not just reduction in lesion counts, according to Barry Resnik, MD.

Clinicians are increasingly facing barriers when attempting to prescribe on-label treatments for indicated patients.

Catch up on coverage from the third day of South Beach Symposium 2026.

GLP-1 therapies represent a paradigm shift requiring dermatology to integrate metabolic, medical, and aesthetic care.

At South Beach Symposium 2026, Mona Shahriari explores OX40/OX40L therapies for atopic dermatitis.

At MOPD 2026, Lisa Swanson, MD, urges fungal cultures amid terbinafine resistance and warns attendees about risky kids’ skin care trends.

At South Beach Symposium 2026, Benjamin Ungar, MD, discussed safer, long-term approaches for seborrheic dermatitis.

Catch up on coverage from the second day of South Beach Symposium 2026.

Glynis Ablon, MD, FAAD, shares insights on diagnosing alopecia fast, managing aesthetic complications, and choosing evidence-based supplements.